Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 10,853 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Tumors
Interventions: Fosbretabulin, Carboplatin, Paclitaxel, Bevacizumab; Drug
Lead sponsor: Mateon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 15
States / cities: Campbell, California • Fountain Valley, California • Los Angeles, California + 12 more

Conditions: IGA Glomerulonephritis
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Medical Device Usage and Evaluation, Physical Performance Testing, Positron Emission Tomography, Survey Administration; Procedure · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 225
States / cities: Fort Smith, Arkansas • Aurora, Colorado • Boulder, Colorado + 160 more

Conditions: Hyponatremia
Interventions: lixivaptan, Placebo; Drug
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 102
States / cities: Birmingham, Alabama • Mobile, Alabama • Bakersfield, California + 82 more

Conditions: Colorectal Carcinoma, CRC
Interventions: JX-594, Irinotecan; Biological · Drug
Lead sponsor: Jennerex Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Scottsdale, Arizona • La Jolla, California • Billings, Montana + 3 more

Conditions: CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Docetaxel, Laboratory Biomarker Analysis, Palbociclib; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1065
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 659 more

Conditions: Primary Refractory Neuroblastoma
Interventions: MAb-3F8, Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), 13-cis-Retinoic Acid; Biological
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Months to 13 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 15
States / cities: Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 12 more

Conditions: Osteoporosis
Interventions: Calcium; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 8 Years to 13 Years · Female only
Enrollment: 354 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1991 – 2001
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Bendamustine Hydrochloride, Bortezomib, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Ofatumumab, Positron Emission Tomography with Radiolabeled Targeting Agent; Drug · Radiation · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 96
States / cities: La Jolla, California • St. Helena, California • Middletown, Connecticut + 70 more

Conditions: Coronary Stenosis
Interventions: TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 58 more

Conditions: Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer
Interventions: Placebo, AMG 655, Modified FOLFOX6, Bevacizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 61
States / cities: Hot Springs, Arkansas • Downey, California • La Jolla, California + 56 more

Conditions: Influenza
Interventions: Nitazoxanide, Oseltamivir, Placebo Oral Tablet, Placebo Oral Capsule; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 1,941 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 136
States / cities: Birmingham, Alabama • Dothan, Alabama • Hoover, Alabama + 121 more

Conditions: Systemic Lupus Erythematosus
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Tucson, Arizona • Beverly Hills, California • Covina, California + 22 more

Conditions: Atrial Fibrillation (AF), Persistant Atrial Fibrillation, Paroxysmal AF
Interventions: Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System; Device
Lead sponsor: Arga Medtech SA; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 14 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
Interventions: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 552
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more

Conditions: Mild Cognitive Impairment (MCI), Alzheimer Disease
Interventions: Donanemab, Aducanumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Fullerton, California • Irvine, California • Sherman Oaks, California + 27 more

Conditions: Atrial Fibrillation
Interventions: Dispersion ablation + PVI, VX1, PVI; Procedure · Device
Lead sponsor: Volta Medical; Industry
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Jacksonville, Florida • St Louis, Missouri + 5 more

Conditions: Geographic Atrophy
Interventions: Lampalizumab, Sham Comparator; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 67
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 60 more

Conditions: Alzheimer´s Disease
Interventions: Lanabecestat, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 2,218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 77
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 58 more

Conditions: Diabetes, Type2 Diabetes, Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 85 Years
Enrollment: 2,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 18
States / cities: Los Angeles, California • Oakland, California • Palo Alto, California + 13 more

Conditions: Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, WHO Grade 2 Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions: Anti-GARP Chimeric Antigen Receptor-T Cells, Biospecimen Collection, Chest Radiography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pheresis, Surgical Procedure; Biological · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF
Interventions: Greater Splanchnic Nerve Ablation, Sham Control; Device
Lead sponsor: Axon Therapies, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more

Conditions: Patellofemoral Pain Syndrome
Interventions: Impairment based approach, PFPS Algorithm approach; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 12 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Columbus, Ohio • Dublin, Ohio • New Albany, Ohio + 1 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Erlotinib, Onartuzumab (MetMab), Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 56
States / cities: Chandler, Arizona • Hayward, California • Modesto, California + 47 more

Search by objective public record fields.

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Calcium and Bone Mass in Young Females

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Evaluation of a Treatment Algorithm for Patients With Patellofemoral Pain Syndrome

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)